Literature DB >> 14966406

A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation.

Yukio Ando1, Hisayasu Terazaki, Masaaki Nakamura, Eiko Ando, Katsuki Haraoka, Taro Yamashita, Mitsuharu Ueda, Hiroaki Okabe, Yutaka Sasaki, Hidenobu Tanihara, Makoto Uchino, Yukihiro Inomata.   

Abstract

BACKGROUND: Liver transplantation has served as a treatment for patients with familial amyloidotic polyneuropathy (FAP) because variant transthyretin (TTR), the pathogenic protein of FAP, is predominantly produced by the liver. However, the effect on amyloid formation of TTR that is synthesised by the retina and the choroid plexus remains to be elucidated in FAP patients with liver transplants.
OBJECTIVE: To investigate changes in ocular tissues and the central nervous system (CNS) of FAP patients after liver transplantation.
DESIGN: Clinical study.
SETTING: Graduate School of Medical Sciences, Kumamoto University, Japan. INTERVENTION: Transplantation of livers from cadaveric or living donors. MEASUREMENTS: Preoperative measures and postoperative (16-108 months) follow-up of clinical data, including routine ophthalmologic, neurologic, and laboratory evaluations.
RESULTS: In 22 patients with FAP related to the amyloidogenic TTR (ATTR) Val30Met and 3 patients with FAP ATTR Tyr114Cys, after liver transplantation, 3 patients began to show evidence of de novo glaucoma, and 1 had vitreous opacity that was caused by the variant TTR. Another three patients showed new amyloid deposits in the pupillary margin, which could lead to glaucoma and vitreous opacity. As for changes in the CNS and levels of total protein and TTR in cerebrospinal fluid (CSF), after liver transplantation, two FAP ATTR Tyr114Cys patients exhibited de novo amyloid deposition in the leptomeninges, and total protein and TTR levels in CSF were significantly increased.
CONCLUSIONS: Oculoleptomeningeal involvement in FAP was not prevented by liver transplantation because variant TTR produced by the retina and the choroid plexus forms amyloid fibrils in situ.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14966406     DOI: 10.1097/01.TP.0000111516.60013.E6

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  17 in total

1.  Leptomeningeal familial amyloidosis: A rare differential diagnosis of leptomeningeal enhancement in MRI.

Authors:  P P Urban; C Hertkorn; J M Schattenberg; J Gawehn; S Hägele; M Wunsch; K Altland
Journal:  J Neurol       Date:  2006-09-21       Impact factor: 4.849

2.  Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation.

Authors:  Yuki Ohya; Sadahisa Okamoto; Masayoshi Tasaki; Mitsuharu Ueda; Hirofumi Jono; Konen Obayashi; Kazuhisa Takeda; Hideaki Okajima; Katsuhiro Asonuma; Ryuhei Hara; Hidenobu Tanihara; Yukio Ando; Yukihiro Inomata
Journal:  Surg Today       Date:  2011-08-26       Impact factor: 2.549

Review 3.  Transthyretin: the servant of many masters.

Authors:  Joel N Buxbaum; Natàlia Reixach
Journal:  Cell Mol Life Sci       Date:  2009-07-31       Impact factor: 9.261

4.  Prevalence of and Factors Associated with Dural Thickness in Patients with Mild Cognitive Impairment and Alzheimer's Disease.

Authors:  Adnan I Qureshi; Iryna Lobanova; Naseeb Ullah; Amna Sohail; Taqi A Zafar; Adil M Malik; Mushtaq H Qureshi
Journal:  J Vasc Interv Neurol       Date:  2015-07

5.  Early onset vitreous amyloidosis in familial amyloidotic polyneuropathy with a transthyretin Glu54Gly mutation is associated with elevated vitreous VEGF.

Authors:  T M O'Hearn; A Fawzi; S He; N A Rao; J I Lim
Journal:  Br J Ophthalmol       Date:  2007-05-23       Impact factor: 4.638

6.  A novel amyloidogenic transthyretin variant, Gly53Ala, associated with intermittent headaches and ataxia.

Authors:  C Douglass; K Suvarna; M M Reilly; P N Hawkins; M Hadjivassiliou
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-13       Impact factor: 10.154

Review 7.  Multidisciplinary Approaches for Transthyretin Amyloidosis.

Authors:  Haruki Koike; Takahiro Okumura; Toyoaki Murohara; Masahisa Katsuno
Journal:  Cardiol Ther       Date:  2021-06-04

Review 8.  Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.

Authors:  Antonia Carroll; P James Dyck; Mamede de Carvalho; Marina Kennerson; Mary M Reilly; Matthew C Kiernan; Steve Vucic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-03-07       Impact factor: 13.654

9.  Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases.

Authors:  João Melo Beirão; Jorge Malheiro; Carolina Lemos; Idalina Beirão; Paulo Costa; Paulo Torres
Journal:  Amyloid       Date:  2015-06-22       Impact factor: 7.141

Review 10.  Ocular Manifestations and Therapeutic Options in Patients with Familial Amyloid Polyneuropathy: A Systematic Review.

Authors:  A C Martins; A M Rosa; E Costa; C Tavares; M J Quadrado; J N Murta
Journal:  Biomed Res Int       Date:  2015-10-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.